Heartbeam, Inc.
1.6000+0.01 (+0.63%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · BEAT · USD
Key Stats
Market Cap
54.90MP/E (TTM)
-Basic EPS (TTM)
-0.69Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
HeartBeam's Q2 FY2025 results show steady operating losses of $5.0M, flat year-over-year but up slightly quarter-on-quarter from Q1's $5.5M (derived), driven by ramped R&D spending on product development and headcount while G&A dipped on lower stock-based comp. Net loss edged to $5.0M from $5.0M last year, with EPS improving to $(0.15) from $(0.19) thanks to more shares outstanding; YTD net loss of $10.5M aligns with diluted shares of 32.2M, no anti-dilution flagged. Cash burn hit $7.9M YTD, offset by $10.7M from February's equity raise, leaving $5.1M in cash and equivalents at quarter-end—no debt, but liquidity falls short of 12-month runway per going concern note. FDA-cleared HeartBeam System advanced with VALID-ECG study's 93.4% diagnostic agreement and AccurKardia tie-up for automated reads. Yet competition from bigger players in cardiac monitoring looms large.
8-K
Annual meeting outcomes
HeartBeam, Inc. held its annual stockholder meeting on July 11, 2025, electing all nine director nominees and ratifying CBIZ CPAs P.C. as auditors for the fiscal year ending December 31, 2025. Shareholders approved amending the 2022 Equity Incentive Plan, boosting authorized shares by 3,000,000 to 11,900,000. This expands equity award capacity. Yet approval was narrow, with 61% in favor amid heavy broker non-votes.
10-Q
Q1 FY2025 results
HeartBeam's Q1 FY2025 results show operating expenses climbing 15% y/y to $5.5M, driven by a 44% jump in R&D to $3.5M from headcount growth and product development, while G&A dipped 15% to $2.0M on lower stock-based comp. This pushed the operating loss to $5.5M, up 15% y/y, with net loss at $5.5M or $(0.18) per diluted share on 30.4M weighted shares—anti-dilution kept basic and diluted equal. No revenue yet, but cash swelled to $8.2M including short-term investments, bolstered by $10.3M net from a February equity offering of 6.7M shares. The VALID-ECG study hit 93.4% diagnostic agreement in April, paving way for 12L software clearance. Liquidity supports milestones, yet funding needs loom large. Competition from larger players shadows progress.
8-K
CEO joins HeartBeam board
HeartBeam expanded its board from eight to nine members by appointing CEO Robert Eno on May 5, 2025, to bolster leadership amid U.S. commercialization push. Eno's 30 years in medtech, including prior CEO roles at Preview Medical and HeartFlow, will sharpen sales strategies for the FDA-cleared 3D ECG technology, with 12-lead synthesis approval pending. This move aligns expertise for market entry. Forward-looking plans hinge on regulatory clearance.
8-K
Auditor transition at HeartBeam
HeartBeam's auditor Marcum resigned on April 21, 2025, after CBIZ CPAs acquired its attest business effective November 1, 2024; the Audit Committee swiftly engaged CBIZ as the new firm for the year ending December 31, 2025. Marcum's prior reports contained no disagreements or adverse opinions, though the 2024 audit flagged going concern doubts and material weaknesses in internal controls—issues now remediated per disclosures. No consultations preceded the switch. Continuity holds firm.
IPO
Website
Employees
Sector
Industry
CBLL
CeriBell, Inc.
12.03-0.80
DH
Definitive Healthcare Corp.
2.77-0.17
HNGE
Hinge Health, Inc.
49.60-1.37
HSCS
HeartSciences Inc.
2.97-0.19
HTFL
Heartflow, Inc.
37.52-0.78
IRTC
iRhythm Technologies, Inc.
185.29+2.62
OHCFF
LIGHT AI INC.
0.12-0.00
ONMD
OneMedNet Corp
2.37+0.17
RMHI
Retrieve Medical Holdings Inc
1.30+0.00
VSEE
VSee Health, Inc.
1.38+0.32